REPEATED BREAST-CONSERVING SURGERIES AS REFLECTION OF THE EVOLUTION IN BREAST CANCER TREATMENT (CASE REPORT WITH LITERATURE REVIEW)
DOI:
https://doi.org/10.15407/exp-oncology.2023.03.386Keywords:
breast cancer, repeated organ-sparing surgery, ipsilateral recurrenceAbstract
The clinical case of a patient with multicentric breast cancer who underwent organ-sparing surgery after neoadjuvant chemo-radiation therapy is presented. An ipsilateral cancer recurrence was diagnosed 8 years after the first operation. The repeated organ-sparing surgery (lumpectomy) was done with a good cosmetic result and without disease progression during 1-year follow-up. The literature review shows that neoadjuvant systemic therapy accounting for molecular subtypes of cancer has radically changed breast cancer surgeries. The evolution of surgical approaches in stage I—II breast cancer patients consists in the de-escalation of surgery from mastectomy to organsparing or oncoplastic surgery, minimally directed surgery, and repeated breast-conserving surgery. De-escalation of surgical interventions in the area of the regional lymphatic collector consists in the transition from total axillary lymphatic dissection to sentinel lymph node biopsy or targeted removal of metastatic lymph nodes. The repeated breast-conserving surgery can be safely performed for ipsilateral recurrence in patients with all molecular subtypes of breast cancer.
References
Mo C, Ruan W, Lin J, et al. Repeat breast-conserving surgery versus salvage mastectomy for ipsilateral breast tumour recurrence after breast-conserving surgery in breast cancer patients: a meta-analysis. Front Oncol. 2021;11:734719. https://doi.org/10.3389/fonc.2021.734719
Van den Bruele AB, Chen I, Sevilimedu V, et al. Management of ipsilateral breast tumor recurrence following breast conservation surgery: a comparative study of re-conservation vs mastectomy. Breast Cancer Res Treat. 2021;187(1):105-112. https://doi.org/10.1007/s10549-020-06080-9
Tollan CJ, Pantiora E, Valachis A, et al. A systematic review and meta-analysis on the role of repeat breast-con- serving surgery for the management of ipsilateral breast cancer recurrence. Ann Surg Oncol. 2022;29:6440-6453. https://doi.org/10.1245/s10434-022-12197-6
Murphy BL, Day CN, Hoskin TL, et al. Neoadjuvant chemotherapy use in breast cancer is greatest in excellent responders: triplenegative and HER2+ subtypes. Ann Surg Oncol. 2018;25(8):2241-2248. https://doi.org/10.1245/s10434-018-6531-5
Heil J, Schaefgen B, Sinn P, et al. Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy? Eur J Cancer 2016; 69: 142-150. https://doi.org/10.1016/j.ejca.2016.09.034
Anderson S. A short history of Bernard Fisher’s contributions to randomized clinical trials. Clin Trials 2022;19(2):127-136. https://doi.org/10.1177/17407745211066498
Fisher B, Bauer M, Margolese R, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med. 1985;312:665-673.
Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194-1220. https://doi.org/10.1093/annonc/mdz173
Kuerer HM, Smith BD, Krishnamurthy S, et al. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2022;23(12):1517-1524. https://doi.org/10.1016/S1470-2045(22)00613-1
Nussbaumer RL,·Maggi N, Castrezana L, et al. The impact of neoadjuvant systemic treatment on postoperative complications in breast cancer surgery. Breast Cancer Res Treat. 2023;197(2):333-341. https://doi.org/10.1007/s10549-022-06811-0
Feng K, Jia Z, Liu G, et al. A review of studies on omitting surgery after neoadjuvant chemotherapy in breast cancer. Am J Cancer Res. 2022;12(8):3512-3531.
Pfob A, Dubsky P. The underused potential of breast conserving therapy after neoadjuvant system treatment — Causes and solutions. Breast. 2023;67:110-115. https://doi.org/10.1016/j.breast.2023.01.008
Kummerow KL, Du L, Penson DF, et al. Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg. 2015;150:9-16. https://doi.org/10.1001/jamasurg.2014.2895
Lautner M, Lin H, Shen Y, et al. Disparities in the use of breast-conserving therapy among patients with early-stage breast cancer. JAMA Surg. 2015;150:778-786. https://doi.org/10.1001/JAMASURG.2015.1102
Pollom EL, Qian Y, Chin AL, et al. Rising rates of bilateral mastectomy with reconstruction following neoadjuvant chemotherapy. Int J Cancer. 2018;143(12):3262-3272. https://doi.org/10.1002/IJC.31747
Galaychuk I. Surgery features in the treatment of patients with Her2-neu positive breast cancer. Oncology. 2020;22(1-2):80-83. https://doi.org/10.32471/oncology.2663-7928.t-22-1-2020-g.8568
Guidolin K, Yaremko B, Lynn K, et al. Stereotactic image-guided neoadjuvant ablative single-dose radiation, then lumpectomy, for early breast cancer: the SIGNAL prospective single-arm trial of single-dose radiation therapy. Curr Oncol Tor Ont. 2019;26:e334-e340. https://doi.org/10.3747/co.26.4479
Zerella MA, Zafaroni M, Ronci G, et al. Single fraction ablative preoperative radiation treatment for early-stage breast cancer: the CRYSTAL study – a phase I/II clinical trial protocol. BMC Cancer. 2022;22(1):358. https://doi.org/10.1186/s12885-022-09305-w
Galaychuk I, Butov S. Organ-saving surgery after preoperative radiotherapy in patients with breast cancer. Me dicina Internacia Revuo (MIR). 2020;29(1):56-63.
Ataseven B, Lederer B, Blohmer JU, et al. Impact of multifocal or multicentric disease on surgery and locore-gional, distant and overall survival of 6,134 breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2015;22(4):1118-1127. https://doi.org/10.1245/S10434-014-4122-7/FIGURES/2.
Simons JM, Koppert LB, Luiten EJT, et al. Deescalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch populationbased study. Breast Cancer Res Treat. 2020;180:725-733. https://doi.org/10.1007/s10549-020-05589-3
Caudle AS, Bedrosian I, Milton DR, et al. Use of sentinel lymph node dissection after neoadjuvant chemotherapy in patients with node-positive breast cancer at diagnosis: practice patterns of American society of breast surgeons members. Ann Surg Oncol. 2017;24(10):2925-2934. https://doi.org/10.1245/s10434-017-5958-4.
Pilewskie M, Morrow M. Axillary nodal management following neoadjuvant chemotherapy: a review. JAMA Oncol. 2017;3(4):549-555. https://doi.org/10.1001/jamaoncol.2016.4163.
Galimberti V, Fontana SKR, Vicini E, et al. This house believes that: Sentinel node biopsy alone is better than TAD after NACT for cN+ patients. Breast. 2022;67:21-25. https://doi.org/10.1016/j.breast.2022.12.010
Reimer T. Omission of axillary sentinel lymph node biopsy in early invasive breast cancer. Breast. 2023;67:124–128. doi: 10.1016/j.breast.2023.01.002
Dilege E, Celik B, Toprak S, et al. SPECT/CT lymphoscintigraphy can accurately localize the sentinel lymph nodes and the clipped node in breast cancer patients undergoing targeted axillary dissection after neoadjuvant chemotherapy. Eur J Cancer. 2022;175(Suppl. 1):S17 (PB-051).
Tasdoven I, Balbaloglu H, Erdemir RU, et al. Triple mapping for axillary staging after neoadjuvant therapy: Axillary reverse mapping with indocyanine green and dual agent sentinel lymph node biopsy. Medicine. 2022;101:52(e32545). http://dx.doi.org/10.1097/MD.0000000000032545
Yoshida A, Takahashi O, Okumura Y, et al. Prognosis after mastectomy versus repeat lumpectomy in patients with ipsilateral breast cancer recurrence: A propensity score analysis. Eur J Surg Oncol. 2016;42(4):474-480. https://doi.org/10.1016/j.ejso.2016.01.011.
Hannoun-Levi J-M, Gal J, Van Limbergen E, et al. Salvage mastectomy versus second conservative treatment for second ipsilateral breast tumor event: a propensity score-matched cohort analysis of the GEC-ESTRO Breast Cancer Working Group Database. Int J Radiat Oncol Biol Physics. 2021;110(2):452-461. https://doi.org/10.1016/j.ijrobp.2020.12.029
Ishitobi M, Fukui R, Hashimoto Y, et al. Safety for repeat lumpectomy without raiotherapy for ipsilateral breast tumor recurrence. Anticancer Res. 2017;37:5293-5299. https://doi.org/10.21873/anticanres.11955
Wilke LG, Czechura T, Wang C, et al. Repeat surgery after breast conservation for the treatment of stage 0 to ii breast carcinoma. a report from the National Cancer Data Base, 2004-2010. JAMA Surg. 2014;149(12):1296-1305. https://doi.org/10.1001/jamasurg.2014.926
Cailleux F, Agostinetto E, Lambertini M, et al. Circulating tumor DNA after neoadjuvant chemotherapy in breast cancer is associated with disease relapse. JCO Precis Oncol. 2022;6:e2200148. doi: 10.1200/PO.22.00148:
Chen X, Li X, Wang J, et al. Breast invasive ductal carcinoma diagnosis with a three-miRNA panel in serum. Biomark. Med. 2021;15(12):951-963. https://doi.org/10.2217/bmm-2020-0785
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
